$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000162828017008455 Filed on August 09, 2017

Income Statement

Concept	2017 Q2	2016 Q2	2014 Q4
Revenue	$102.0K	$104.0K	$56.00K
YoY Change	-1.91%	112.24%	19.15%
Cost Of Revenue	$338.2K	$409.5K	$20.00K
YoY Change	-17.4%	411.64%
Gross Profit	-$236.2K	-$305.5K	$40.00K
YoY Change	-22.68%	884.41%
Gross Profit Margin	-231.54%	-293.71%	71.43%
Selling, General & Admin	$4.674M	$5.598M	$3.570M
YoY Change	-16.5%	42.9%	91.94%
% of Gross Profit			8925.0%
Research & Development	$981.7K	$4.076M	$970.0K
YoY Change	-75.92%	51.87%	-6.73%
% of Gross Profit			2425.0%
Depreciation & Amortization	$320.0K	$330.0K	$60.00K
YoY Change	-3.03%	312.5%	50.0%
% of Gross Profit			150.0%
Operating Expenses	$5.990M	$10.08M	$4.560M
YoY Change	-40.6%	50.91%	57.24%
Operating Profit	-$5.888M	-$9.980M	-$4.520M
YoY Change	-41.0%	50.48%
Interest Expense	-$500.0K	-$220.0K	-$180.0K
YoY Change	127.27%	-93.82%	-109.78%
% of Operating Profit
Other Income/Expense, Net	$1.566K	$0.00	-$20.00K
YoY Change		-100.0%
Pretax Income	-$8.050M	-$10.20M	-$4.680M
YoY Change	-21.08%	0.2%	354.37%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$8.046M	-$10.20M	-$4.680M
YoY Change	-21.14%	0.22%	354.37%
Net Earnings / Revenue	-7887.2%	-9809.88%	-8357.14%
Basic Earnings Per Share	-$3.12	-$0.34	-$0.25
Diluted Earnings Per Share	-$3.12	-$0.34	-$0.25
COMMON SHARES
Basic Shares Outstanding	2.583M shares	29.96M shares	18.90M shares
Diluted Shares Outstanding	2.583M shares	29.96M shares	19.07M shares

Balance Sheet

Concept	2017 Q2	2016 Q2	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.800M	$50.60M	$27.30M
YoY Change	-84.58%	22.52%	5.81%
Cash & Equivalents	$7.784M	$22.58M	$67.49M
Short-Term Investments	$0.00	$28.00M
Other Short-Term Assets	$700.0K	$900.0K	$400.0K
YoY Change	-22.22%	80.0%	100.0%
Inventory
Prepaid Expenses
Receivables	$157.4K	$158.5K	$56.69K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.655M	$51.62M	$27.72M
YoY Change	-83.23%	23.2%	6.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.322M	$4.732M	$840.4K
YoY Change	-29.8%	237.98%	11.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$584.0K	$371.2K	$336.7K
YoY Change	57.3%	-7.19%	0.08%
Total Long-Term Assets	$3.906M	$5.103M	$1.177M
YoY Change	-23.47%	200.18%	8.29%
TOTAL ASSETS
Total Short-Term Assets	$8.655M	$51.62M	$27.72M
Total Long-Term Assets	$3.906M	$5.103M	$1.177M
Total Assets	$12.56M	$56.72M	$28.90M
YoY Change	-77.86%	30.1%	6.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$602.7K	$1.115M	$747.8K
YoY Change	-45.96%	1.39%	160.91%
Accrued Expenses	$4.930M	$3.627M	$1.842M
YoY Change	35.91%	141.8%	20.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.600M	$6.100M	$1.900M
YoY Change	-73.77%	165.22%	850.0%
Total Short-Term Liabilities	$7.462M	$10.89M	$4.488M
YoY Change	-31.47%	117.78%	123.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$9.000M	$13.10M
YoY Change	-100.0%	-30.23%	4266.67%
Other Long-Term Liabilities	$1.600M	$1.519M	$3.000M
YoY Change	5.32%	-80.27%	-31.82%
Total Long-Term Liabilities	$1.600M	$1.519M	$16.10M
YoY Change	5.32%	-92.63%	242.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.462M	$10.89M	$4.488M
Total Long-Term Liabilities	$1.600M	$1.519M	$16.10M
Total Liabilities	$9.050M	$24.15M	$20.55M
YoY Change	-62.53%	-5.29%	203.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$166.2M	-$129.4M	-$81.39M
YoY Change	28.45%		21.4%
Common Stock	$3.108K	$3.015K	$1.891K
YoY Change	3.08%		0.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.511M	$32.57M	$8.350M
YoY Change
Total Liabilities & Shareholders Equity	$12.56M	$56.72M	$28.90M
YoY Change	-77.86%	30.1%	6.41%

Cashflow Statement

Concept	2017 Q2	2016 Q2	2014 Q4
OPERATING ACTIVITIES
Net Income	-$8.046M	-$10.20M	-$4.680M
YoY Change	-21.14%	0.22%	354.37%
Depreciation, Depletion And Amortization	$320.0K	$330.0K	$60.00K
YoY Change	-3.03%	312.5%	50.0%
Cash From Operating Activities	-$4.600M	-$8.070M	-$3.870M
YoY Change	-43.0%	48.07%	108.06%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$320.0K	-$120.0K
YoY Change	-96.88%	-27.27%	50.0%
Acquisitions
YoY Change
Other Investing Activities	$18.86M	-$27.95M	$60.00K
YoY Change	-167.48%
Cash From Investing Activities	$18.86M	-$28.27M	-$60.00K
YoY Change	-166.71%	6325.0%	-25.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-16.66M	-1.060M	60.00K
YoY Change	1471.7%	-133.23%	-300.0%
NET CHANGE
Cash From Operating Activities	-4.600M	-8.070M	-3.870M
Cash From Investing Activities	18.86M	-28.27M	-60.00K
Cash From Financing Activities	-16.66M	-1.060M	60.00K
Net Change In Cash	-2.400M	-37.40M	-3.870M
YoY Change	-93.58%	1285.19%	96.45%
FREE CASH FLOW
Cash From Operating Activities	-$4.600M	-$8.070M	-$3.870M
Capital Expenditures	-$10.00K	-$320.0K	-$120.0K
Free Cash Flow	-$4.590M	-$7.750M	-$3.750M
YoY Change	-40.77%	54.69%	110.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37269581	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	Trovagene, Inc.
CY2016Q2	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	-533750	USD
CY2017Q2	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Amortized Portion Of Final Fee Upon Repayment AmortizedPortionOfFinalFeeUponRepayment	181318	USD
	trov	Amortized Portion Of Final Fee Upon Repayment AmortizedPortionOfFinalFeeUponRepayment	293614	USD
	trov	Class Of Warrant Or Right Number Expired ClassOfWarrantOrRightNumberExpired	1177024	shares
CY2016	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P1Y7M6D
	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P1Y5M3D
	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	68000	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	12120	USD
CY2016Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	3.83
CY2017Q2	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	3.42
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Expired ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired	5.32
CY2016Q2	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-10204351	USD
	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-20473580	USD
CY2017Q2	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-8051895	USD
	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-18060345	USD
CY2016Q2	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	23962	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	31580	USD
CY2017Q2	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	55501	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	84363	USD
	trov	Leaseholdimprovementspaidforbylessor Leaseholdimprovementspaidforbylessor	1860000	USD
	trov	Leaseholdimprovementspaidforbylessor Leaseholdimprovementspaidforbylessor	0	USD
CY2015Q4	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	3100	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	12120	USD
	trov	Stock Issued During Period Restricted Stock Units StockIssuedDuringPeriodRestrictedStockUnits	278000	shares
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1130536	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	602738	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	100460	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	157445	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-27481	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-9230	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4021365	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4929631	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1761985	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2266297	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10773	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13650	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	167890984	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	169693921	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1301913	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4113021	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	775385	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1696184	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	52641	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	113780	USD
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	-66689	USD
	us-gaap	Amortization Of Deferred Leasing Fees AmortizationOfDeferredLeasingFees	-136776	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11113067	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9433438	shares
CY2017Q2	us-gaap	Area Of Land AreaOfLand	26100	sqft
CY2015Q4	us-gaap	Area Of Land AreaOfLand	2300	sqft
CY2016Q4	us-gaap	Assets Assets	43950411	USD
CY2017Q2	us-gaap	Assets Assets	12560754	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	8655249	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	374	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	38950192	USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9439	USD
CY2016Q4	us-gaap	Available For Sale Securities Short Term Investments Amortized Cost AvailableForSaleSecuritiesShortTermInvestmentsAmortizedCost	23987087	USD
	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	0	USD
	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	-6400	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67493047	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22578980	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13915094	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7783891	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5505901	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4328877	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30696791	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31076872	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30696791	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31076872	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	3070	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	3108	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10198291	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20461460	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8045835	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18048225	USD
CY2016Q2	us-gaap	Cost Of Revenue CostOfRevenue	409463	USD
	us-gaap	Cost Of Revenue CostOfRevenue	718734	USD
CY2017Q2	us-gaap	Cost Of Revenue CostOfRevenue	338203	USD
	us-gaap	Cost Of Revenue CostOfRevenue	954629	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	285246	USD
CY2017Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	285246	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1373717	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1236941	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	489708	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	645962	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	834940	USD
CY2017Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	350862	USD
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-2473	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	280520	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2411	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-28097	USD
CY2016Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1655825	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1655825	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2468732	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6472979	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4059133	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6255772	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4560	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1481532	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	59801	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	56985	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	75300	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	90330	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2761	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	88678	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-243571	USD
CY2016Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	176596	shares
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2016Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-274909	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-612529	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-431871	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-861268	USD
	us-gaap	Interest Paid InterestPaid	536727	USD
	us-gaap	Interest Paid InterestPaid	629952	USD
CY2016Q4	us-gaap	Liabilities Liabilities	24182272	USD
CY2017Q2	us-gaap	Liabilities Liabilities	9049985	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43950411	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12560754	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7797256	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7462182	USD
CY2017Q2	us-gaap	Litigation Reserve LitigationReserve	2100000	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	14176359	USD
CY2017Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	0	USD
CY2016Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2360109	USD
CY2017Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1644567	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-44914067	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-6131203	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1295688	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-16819328	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-28622478	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	24041048	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14993428	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13355334	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-10202278	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20464796	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-8045811	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18045348	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10208338	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20476916	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8051871	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18057468	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10208338	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21010666	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8051871	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-18057468	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	10083645	USD
	us-gaap	Operating Expenses OperatingExpenses	20662779	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	5990264	USD
	us-gaap	Operating Expenses OperatingExpenses	16210948	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9980245	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20438893	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5888253	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16013899	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1173304	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	583973	USD
CY2016Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1145	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1796	USD
CY2017Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-9543	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-11942	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3987	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	3336	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-24	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2877	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5132	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5132	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9519	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9065	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1566	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1566	USD
CY2016Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	31673	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	31673	USD
CY2017Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	1700	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	2050	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1613067	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	27951611	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8804604	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	670867	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20738	USD
CY2016Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12120	USD
CY2017Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12120	USD
CY2016Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	606000	USD
CY2017Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	606000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	60600	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	60600	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	956616	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	713913	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	106791	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	100000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	792251	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	16431837	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	16434553	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	232144	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5588900	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5587829	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3826915	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3321532	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2320083	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	15000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	0	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	313052	USD
CY2016Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4076414	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	7284478	USD
CY2017Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	981715	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5261545	USD
CY2017Q2	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	2000000	USD
CY2016Q2	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	0	USD
	us-gaap	Restructuring Charges RestructuringCharges	1700000	USD
CY2017Q2	us-gaap	Restructuring Charges RestructuringCharges	-3806	USD
	us-gaap	Restructuring Charges RestructuringCharges	1715998	USD
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	USD
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	485000	USD
CY2017Q2	us-gaap	Restructuring Reserve RestructuringReserve	800000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148115202	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-166172670	USD
CY2016Q2	us-gaap	Royalty Revenue RoyaltyRevenue	47765	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	160633	USD
CY2017Q2	us-gaap	Royalty Revenue RoyaltyRevenue	44810	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	110636	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	103400	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	223886	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	102011	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	197049	USD
CY2016Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3129036	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6186588	USD
CY2017Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	615019	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2023004	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4113021	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1696184	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	580180	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4181755	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2796924	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	23978022	USD
CY2017Q2	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	19768139	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	3510769	USD
CY2016Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	52876	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	586626	USD
CY2017Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-71428	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	484078	USD
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29958037	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30033207	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30991740	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30976462	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29958037	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29856611	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30991740	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30976462	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:45px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-008455-index-headers.html	Edgar Link	pending
0001628280-17-008455-index.html	Edgar Link	pending
0001628280-17-008455.txt	Edgar Link	pending
0001628280-17-008455-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-063017exhibit311.htm	Edgar Link	pending
trov-063017exhibit321.htm	Edgar Link	pending
trov-063017x10q.htm	Edgar Link	pending
trov-20170630.xml	Edgar Link	completed
trov-20170630.xsd	Edgar Link	pending
trov-20170630_cal.xml	Edgar Link	unprocessable
trov-20170630_def.xml	Edgar Link	unprocessable
trov-20170630_lab.xml	Edgar Link	unprocessable
trov-20170630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2017 Q2 Form 10-Q Financial Statement

#000162828017008455 Filed on August 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2017 Q2 Form 10-Q Financial Statement

#000162828017008455 Filed on August 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf